TrialInternational journal of clinical pharmacology and therapeutics2022

A randomized, double-blind, three-arm, parallel group, single-dose phase I study to evaluate the pharmacokinetic similarity between SB12 (a proposed eculizumab biosimilar) and eculizumab (Soliris) in healthy subjects.

Hyun A Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.